Delivery Order SPE2DE21D0005-SPE2D625F0BA1
- Not listed
- Organogenesis Inc., a Canton, Massachusetts-based regenerative medicine company, received a delivery order award valued at $1,239.95 from the Defense Logistics Agency's Medical Supply Chain for APLIGRAF, an advanced wound care and tissue regeneration product. The contract, awarded on May 7, 2025, carries a fixed price structure with economic price adjustment provisions and is scheduled for completion by May 12, 2025. No set-aside designation was used in this award, indicating Organogenesis...
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a delivery order valued at $2,479.90 for APLIGRAF on May 30, 2025, with an ultimate completion date of June 4, 2025. This fixed-price contract with economic price adjustment was issued by the Medical Supply Chain, a defense-focused federal agency, with no set-aside designation applied. APLIGRAF is an advanced wound care and tissue regeneration product that falls within Organogenesis's core portfolio...
- On May 12, 2025, the Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $1,239.95 to Organogenesis Inc. for APLIGRAF, an advanced regenerative medicine product used in wound care and tissue regeneration. The contract is classified as fixed price with economic price adjustment and carries an ultimate completion date of May 15, 2025. This delivery order was issued without set-aside designation, reflecting Organogenesis's status as a standard commercial vendor...
- This federal contract award is to Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts. The contract, valued at $2,479.90, is a delivery order issued under the Defense Logistics Agency (DLA) Troop Support Medical Indefinite Delivery Contract. The award is for the supply of the APLIGRAF advanced wound care product, a specialized skin substitute and tissue regeneration solution used in medical treatments. The contract does not utilize any set-aside...
- This is a $1,239.95 fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to Organogenesis Inc., a regenerative medicine company. The order is for the company's APLIGRAF product, which is a wound dressing and tissue regeneration solution. Organogenesis has been awarded numerous prime federal contracts by the DLA and Department of Veterans Affairs (VA) to provide advanced wound care and surgical products. This specific award is not associated with a set-aside program....
- This federal contract award, valued at $1,239.95, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Organogenesis Inc., a for-profit manufacturer of regenerative medical products based in Canton, Massachusetts. The contract is a delivery order for the APLIGRAF skin substitute product, with a period of performance through May 1, 2025. This award is not associated with a set-aside designation, indicating Organogenesis competes as a standard commercial vendor....
- This is a federal contract award to Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts. The contract, awarded by the Defense Logistics Agency (DLA) Troop Support Medical, is for the delivery of APLIGRAF, a skin substitute product. The contract is a Delivery Order, with a Ceiling Value of $1,239.95, and a Fixed Price with Economic Price Adjustment pricing type. The contract has an Ultimate Completion Date of April 17, 2025. Organogenesis Inc. is a for-profit...
- Organogenesis Inc., a regenerative medicine company based in Canton, Massachusetts, was awarded a delivery order valued at $3,400 on July 17, 2025, by the Defense Logistics Agency's Medical Supply Chain division. The delivery order, which carries a fixed-price contract type with economic price adjustment provisions, is for PURAPLY AM XT EF, a 5-layer fenestrated advanced wound care product. The contract does not utilize a set-aside designation, indicating Organogenesis competed as a standard...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a $1,239.95 Delivery Order (SPE2DE21D0005|SPE2D625F228P) to Organogenesis Inc., a for-profit manufacturer of regenerative medicine products. The award is for the delivery of the advanced wound care product APLIGRAF. The order is a Fixed Price with Economic Price Adjustment contract with a completion date of November 1, 2024. Organogenesis, headquartered in Canton, Massachusetts, is a key supplier of medical products to federal...
- This federal contract award to Organogenesis Inc., a leading regenerative medicine company, is for the delivery of APLIGRAF, a tissue regeneration product. The $1,239.95 fixed-price with economic price adjustment contract was awarded by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency, and has a completion date of September 25, 2024. Organogenesis holds several significant Indefinite Delivery Vehicles (IDVs) with federal agencies, including a $25 million single-award...
- SPE2DE21D0005Indefinite Delivery Contract
- SPE2DE21D0005-SPE2D625F0BA1Delivery Order
Organogenesis Inc., a regenerative medicine company headquartered in Canton, Massachusetts, was awarded a delivery order valued at $1,239.95 for APLIGRAF, an advanced wound care and tissue regeneration product. The contract, awarded on May 30, 2025, with an ultimate completion date of June 4, 2025, utilizes fixed-price pricing with economic price adjustment terms. The award was made without a set-aside designation, indicating that Organogenesis competed as a standard commercial vendor. The Medical Supply Chain organization within the Defense department is the funding federal agency for this delivery order. This delivery order is likely issued under one of Organogenesis's existing Indefinite Delivery Vehicles, which position the company as a key supplier of regenerative medicine solutions to government healthcare systems. The company maintains several significant federal contract vehicles, including a $49.5 million multiple-award Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical and a $25 million single-award contract with the Veterans Affairs Headquarters for Surgical Implant Next Generation products. APLIGRAF, a specialized skin substitute used for advanced wound treatment, continues Organogenesis's established role in supplying critical wound care and tissue regeneration products to support medical treatments for military personnel and veterans.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 5/30/25 |